Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA generic biologics document delayed

Executive Summary

Development of FDA background document on generic biologics is delayed while senior management addresses drug safety issues raised during the year. The goal of the document is to harmonize review practices of biologics used to treat different diseases; it was due out in 2004 (1"The Pink Sheet" Nov. 1, 2004, p. 16)...

You may also be interested in...



FDA Follow-On Biologics Background Document To Be Released By Year-End

FDA is developing a background document as part of its ongoing action on "follow-on" biologics, Acting Commissioner for Operations Janet Woodcock, MD, said

COVID-19 Flexibility For Telehealth Payments Should Be Made Permanent, Telemedicine Group Tells CMS

The American Telemedicine Association backed use of more telehealth providers and changes to remote monitoring reimbursements in comments to the US Medicare agency.

STADA Strengthens Specialty Partnership Role Via US Filing

STADA Strengthens Specialty Partnership Role Via US Filing

Topics

UsernamePublicRestriction

Register

MT142539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel